Media coverage about Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neovasc Inc (US) earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.8537145422207 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern’s scoring:

Neovasc Inc (NVCN) traded up $0.01 during mid-day trading on Tuesday, hitting $0.35. 3,267,500 shares of the stock traded hands, compared to its average volume of 1,660,955. The stock has a market cap of $35.36, a price-to-earnings ratio of 1.30 and a beta of 1.23. Neovasc Inc has a 1 year low of $0.31 and a 1 year high of $2.12.

Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last released its quarterly earnings results on Tuesday, November 14th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a net margin of 268.35% and a negative return on equity of 85.81%. equities research analysts predict that Neovasc Inc will post -0.21 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on NVCN shares. Canaccord Genuity restated a “buy” rating and set a $1.05 target price on shares of Neovasc Inc (US) in a report on Friday, January 19th. Zacks Investment Research cut Neovasc Inc (US) from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Finally, ValuEngine cut Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Neovasc Inc (US) presently has a consensus rating of “Hold” and an average price target of $2.95.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Neovasc Inc (US) (NVCN) Stock Price” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at

Neovasc Inc (US) Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Insider Buying and Selling by Quarter for Neovasc Inc (US) (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.